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SUMMARY – Anemia is a frequent complication of lymphoid neoplasms as a result of the 
disease and myelotoxic chemotherapy, and has a significant impact on treatment outcome, survival 
and quality of life. The aim of this study was to investigate clinical characteristics of anemia in lymp-
hoid malignancies and to assess the need of anemia treatment in the context of modern therapeutic 
possibilities. Fifty-five patients (32 female and 23 male) with non-Hodgkin’s lymphoma (NHL, 
n=30), chronic lymphocytic leukemia (CLL, n=8) and multiple myeloma (MM, n=17) were included 
in the study. The influence of age, sex, type of malignancy and chemotherapy on the prevalence, 
severity and type of anemia before and after chemotherapy was analyzed. The prevalence of anemia 
was 51.02% before (A1) and 55.31% after (A2) chemotherapy. Women had a higher prevalence of 
anemia than men (63% vs. 43%), but the severity was higher in men at the beginning (103 vs. 99 
g/L Hb) and at the end of treatment (101 vs. 89 g/L Hb). The highest prevalence of anemia was 
found in MM (69%), followed by NHL (44.4%) and CLL (40%) before chemotherapy, and in MM 
(68.7%), CLL (42.9%) and NHL (20.8%) after chemotherapy. The prevailing anemia was anemia 
of chronic disease (53.8%), followed by anemia due to multiple causes (anemia of chronic disease + 
iron deficiency anemia or anemia of chronic disease + hemolytic anemia; 30.7%), anemia due to iron 
deficiency (11.5%) and hemolytic anemia (7.6%). The prevalence of anemia as a consequence of the 
disease is high in lymphoproliferative disease, but there was no significant rise under chemotherapy, 
even showing a decline in NHL patients (44% vs. 21%), however, the severity of anemia increased. 
Since stage 1 anemia according to the WHO prevailed, only a small number of patients required 
transfusion therapy. About 27% of all patients had hemoglobin values <100 g/L during chemothe-
rapy and could be candidates for erythropoiesis-stimulating agent treatment. 
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Introduction 
Anemia is a common diagnosis in cancer patients 
and depends on the type of malignant disease and 
type of therapy applied. The prevalence and type of 
anemia in cancer patients vary from disease to disease 
and are influenced by different factors like patient age, 
introduction of chemotherapy, and others. In cancer 
patients aged over 70, the prevalence of anemia in-
creases to 70%-80%. According to previous investiga-
tions, the average prevalence of anemia was 40%-50% 
in colon cancer, 70% in ovarian cancer, and 90% after 
platinum-based chemotherapy. The etiology of anemia 
in patients with malignancies may include neoplastic 
cell bone marrow infiltration, particularly in hema-
tologic malignancies, nutritional deficiencies (iron, 
vitamin B12 and folate), hemolysis, and treatment- or 
disease-induced bone marrow suppression as the most 
common reason1,2.
Lymphoid malignancies have become ever more 
frequent among malignant diseases. The prevalence 
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of anemia, according to various studies, ranges be-
tween 40% and 80%. Anemia has been incorporated 
in the prognostic indices for lymphoid malignancies 
as an independent factor of disease severity and prog-
nosis. On the other hand, anemia is a major cause of 
weakness and general bad feeling. Fatigue caused by 
anemia is the most common and long-lasting symp-
tom in patients with hematologic malignancies. Poor 
quality of life is in direct correlation with the degree 
of anemia in cancer patients. Improving the quality 
of life in cancer patients treated with chemotherapy 
and those with advanced disease having undergone 
palliative measures only has become the main goal of 
treating anemia in these patients. The stage and type 
of anemia determine therapeutic approach1-3. 
Despite the high prevalence and broad implica-
tions, the number of patients treated for anemia in 
hematologic malignancies remains relatively low, 
about 50%4. New treatment options include eryth-
ropoiesis-stimulating agents (ESA) and continuous 
erythropoietin receptor activators (CERA), which 
are still in the phase of research. After years of clini-
cal experience with ESA, it is obvious that correction 
of anemia in patients with malignancies is possible. 
The latest guidelines have been designed upon these 
experiences and include definition, identification and 
optimal treatment of anemia in malignant disease. 
Organizations such as the European Organisation for 
Research and Treatment of Cancer (EORTC), the 
National Comprehensive Cancer Network (NCCN), 
the American Society of Hematology (ASH) and the 
American Society of Clinical Oncology (ASCO) rec-
ommend treatment guidelines that suggest interven-
tion with erythropoietin therapy when hemoglobin 
(Hb) concentration decreases below 100-110 g/L4,5.
The aim of this study was to investigate clinical 
characteristics of anemia in lymphoid malignancies 
before and after chemotherapy administration, to as-
sess the need of treatment of anemia and to evaluate 
this treatment in the context of modern possibilities 
available.
Patients and Methods 
Fifty-five patients with non-Hodgkin’s lymphoma 
(NHL), chronic lymphocytic leukemia (CLL) and 
multiple myeloma (MM) not previously treated with 
iron, transfusion, folate or vitamin B12 were included 
in the study. There were 23 male patients (mean age 
66 years) and 32 female patients (mean age 63 years). 
CLL was diagnosed in eight, MM in 17 and NHL 
in 30 patients. The most common chemotherapy 
regimens were CHOP, CVP, chlorambucil, MP, and 
VAD, including the new generation of chemothera-
peutic agents like rituximab. The mean number of 
chemotherapy cycles per patient was 5.9. 
All patients underwent the following investiga-
tions before and after chemotherapy: complete hemo-
gram with red blood cell (RBC) indices, reticulocyte 
count (RTC), peripheral blood smear examination, 
direct Coombs test (DCT), bone marrow aspiration 
(only before therapy), serum iron (SI), ferritin (SF), 
total iron binding capacity (TIBC), percentage satu-
ration (psat) and parameters of disease activity, i.e. 
C-reactive protein (CRP) and lactate dehydrogenase 
(LDH). Hemoglobin level below 120 g/L (normal: 
male 160-180 g/L and female 140-160 g/L) was taken 
as the limit of anemia, while the severity of anemia 
was classified according to the World Health Organi-
zation (WHO) scale (Table 1)1. Anemia was catego-
rized as due to either anemia of chronic disease (ACD; 
SF >300 mcg/L); iron deficiency anemia (IDA; psat 
<20% and SF <100); autoimmune hemolytic anemia 
(AIHA; DCT positive); and anemia due to multiple 
causes (MA), e.g., a combination of IDA and ACD 
(psat  <20%, SF 30-200 with TIBC <42 µmol/L).
The standard methods of descriptive statistics were 
used in the study. Differences between the groups 
were tested using Student’s t-test, χ2-test, Wilcoxon 
test and Kruskal-Wallis test in the Statistica 7 pro-
gram.
Table 1. The World Health Organization anemia grading 
system
Severity according to WHO Hemoglobin (g/L)
Grade 0 110-119
Grade 1 (mild) 95-109
Grade 2 (moderate) 80-94
Grade 3 (serious/severe) 65-79
Grade 4 (life-threatening) <65
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Results 
The mean hemoglobin concentration for the whole 
group was 116.0±19.9 g/L before (Hb1) and 111.1±27.3 
g/L after (Hb2) chemotherapy cycles (P>0.05). There 
was no statistically significant difference between the 
hemoglobin concentrations in men (Hb1 120, Hb2 114 
g/L) and women (Hb1 112, Hb2 109 g/L) (Table 2). 
The difference in hemoglobin values was statisti-
cally significant according to diagnosis (NHL vs. MM 
vs. CLL) both before (Hb1 121 vs. 101 vs. 124 g/L; 
P=0.0331) and after chemotherapy (Hb2 119 vs. 102 vs. 
120 g/L; P=0.0029). MM had significantly lower he-
moglobin concentrations than other groups (Table 2).
The overall prevalence of anemia in lymphoid ma-
lignancies in this study was 51.02% before and 55.31% 
after chemotherapy (P>0.05). The prevalence of ane-
mia in CLL group was 40% with Hb1 mean value of 
101 g/L and 42.9% with Hb2 mean value of 99 g/L. 
In MM group, the prevalence was 69.1% with mean 
Hb1 of 98 g/L and 68.7% with mean Hb2 106 g/L. 
The prevalence of anemia in NHL group was 44.4% 
with mean Hb1 105 g/L and 20.8% with mean Hb2 
value 112 g/L (Table 2). 
The prevalence of anemia in men was 43% with 
mean Hb1 99 g/L and 47% with mean Hb2 89.2 g/L 
(P=0.0003). In women, the prevalence of anemia was 
62.9% with mean Hb1 103 g/L and 58.6% with mean 
Hb2 101 g/L (P>0.05) (Table 2). 
The grade and severity of anemia according to the 
WHO scale according to age, sex and diagnosis are 
shown in Table 3. It is obvious that there was no sig-
nificant increase in the overall prevalence of anemia 
after chemotherapy related to diagnosis, however, the 
severity of anemia showed an increase. 
ACD was the most common type of anemia 
(53.8%, 14/26 patients), MA was present in 30.7%, 
IDA in 11.5% and AIHA in 7.6% of all patients. 
There were no statistically significant differences be-
fore and after chemotherapy in other variables (RTC, 
SI, TIBC, SF, CRP and LDH) tested in this study, 
but they had a tendency to improve. Also, the value 
of LDH in NHL group was significantly lower after 
chemotherapy (P=0.0345). 
Discussion
The type of tumor disease and treatment option 
(chemotherapy and/or radiotherapy) have a signifi-
cant impact on hemogram and the occurrence of ane-
mia. The severity of anemia at diagnosis is a sign of 
the disease severity and has an unfavorable effect on 
Table 2. Values of hemoglobin (Hb) and prevalence of anemia in patients with lymphoid malignancies before and after 
treatment according to sex, age and type of lymphoid neoplasm
n Hb1 (g/L) A1 (%) Hb2 (g/L) A2 (%) P (Hb1:Hb2) P (A1:A2)
Sex
Male 23 120±21.29 99.0 (42.8%) 114±29 89.0 (47.3%) 0.518 0.003
Female 32 113±18.6 103.0 (62.9%) 109±26.5 101.0 (58.6%) 0.4561 0.272
Total 55 116±19.9 102.0 (54%) 111±27.3 97.0 (55%) 0.3331 0.2727
Age
≤65 yrs 22 119±23.8 96.0 (42%) 113±26.2 94.0 (58%) 0.0007 0.8003
>65 yrs 33 114±17.1 104.0 (62%) 112±21.2 97.0 (52%) 0.6933 0.1952
Type of malignancy
NHL 30 121±19.7 105.0 (44%) 119±22.3 112.0 (21%) 0.3045 0.2334
MM 17 102±14.9 98.0 (69%) 102±15.39 106.0 (68.7%) 0.0231 0.4408
CLL 8 124±19.5 101.0 (40%) 120±28.4 99.0 (43%) 0.715 0.5176
A = Hb values and prevalence of anemia before (1) and after (2) chemotherapy; Hb = Hb values for the whole group before (1) and after 
(2) chemotherapy; NHL = non-Hodgkin’s lymphoma; MM = multiple myeloma; CLL = chronic lymphocytic leukemia
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patient outcome. Anemia has been taken in various 
models to predict outcome in patients with hemato-
logic neoplasms like multiple myeloma, Hodgkin’s 
lymphoma, NHL and CLL. Anemia was included in 
the prognostic index of multiple myeloma by Durie 
and Salmon, where the hemoglobin level <85 g/L was 
associated with greater tumor mass and poor survival. 
In Hodgkin’s lymphoma, anemia with hemoglobin 
level <105 g/L is one of the most powerful predic-
tors of poor outcome. Anemia has long been recog-
nized as an important prognostic factor of indolent 
and aggressive lymphoma. Anemia did not become 
part of the International Prognostic Index (IPI) be-
cause it was not tested when the index was developed. 
Including hemoglobin less than 120 in IPI signifi-
cantly increases the index accuracy to predict survival 
and detect treatment failure. After introducing IPI 
in clinical practice, a prognostic index for follicular 
lymphoma (FLIPI) was developed taking hemoglo-
bin level lower than 120 g/L. Follicular lymphoma is 
the most common indolent lymphoma and the second 
most prevalent of all lymphomas. In CLL patients, 
anemia is included in the Rai and Binet index and 
is associated with poor disease outcome6-9. According 
to the British and French authors, the incidence of 
anemia in patients with NHL and Hodgkin’s disease 
at diagnosis is 30%-40% and increases to 70% after 
chemotherapy. In 1763 Italian cancer patients, the 
prevalence of anemia was 56% before and 73% after 
treatment. The high prevalence of anemia is associated 
with lymphoid malignancies, and according to various 
studies is 22%-82% before and 55%-88% after chemo-
therapy10-12. The results of the present study are con-
sistent with the results reported by other authors. The 
mean prevalence of anemia in lymphoid malignancies 
was 51% before and 55% after treatment. The highest 
percentage of patients with anemia was in MM group. 
In this group, the stage of anemia was most severe 
because most patients had the highest grade of disease 
(grade 3 according to Salmon and Durie). The preva-
lence of anemia in CLL and NHL groups was very 
similar, about 40%. In this study, we found a higher 
prevalence of anemia in female than in male patients 
(63% vs. 43%), however, men had a higher grade of 
anemia than women (Hb1 99 vs. 103 g/L) before and 
after (Hb2 89 vs. 101 g/L) treatment. 
The incidence of anemia in lymphoid malignan-
cies investigated in this study was not significantly 
increased after chemotherapy, but we detected pro-
gression in the severity of anemia as a result of my-
elotoxicity. Even more, the overall prevalence of ane-
mia in NHL and MM groups was slightly lower after 
therapy, interpreted as a good therapeutic response. 
Study results showed a significant LDH decrease in 
Table 3. Prevalence of different stages of anemia according to WHO scale according to sex, age and type of malignancy 
before and after treatment
Sex
 Before chemotherapy After chemotherapy
Gr 0-1 Gr 2 Gr >=3 Gr 0-1 Gr 2 Gr >=3
n Hb 95-120 Hb 80-95 Hb <=80 Hb 95-120 Hb 80-95 Hb <=80
Male 9 67% 33% 0% 33% 60% 7%
Female 17 54% 46% 0% 91% 9% 0%
Total 26 69% 27% 0% 62% 23% 19%
Age
≤65 yrs 10 60% 20% 20% 50% 37% 13%
>65 yrs 18 78% 22% 0% 53% 27% 20%
Type of malignancy
NHL 12 83% 8% 8% 50% 0% 50%
MM 11 54% 46% 0% 83% 17% 0%
KLL 3 100% 0% 0% 0% 100% 0%
NHL = non-Hodgkin’s lymphoma; MM = multiple myeloma; CLL = chronic lymphocytic leukemia
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NHL after treatment (as an independent factor of dis-
ease activity). 
Besides the unfavorable impact on disease outcome 
and treatment outcome, anemia has a proven impact 
on the patient quality of life. It is generally consid-
ered that treatment of anemia results in better overall 
survival and disease-free survival, but still there are 
no well structured and prospective studies to prove 
it. According to Functional Assessment of Cancer 
Therapy (Anemia Scale quality of life survey), there 
is direct negative correlation between quality of life 
and severity of anemia. Improvement in the quality 
of life in cancer patients during chemotherapy and in 
those with advanced disease on palliative regimen has 
become the main goal of treating anemia in these pa-
tient populations1-5. The treatment of anemia in cancer 
patients depends on the cause and severity of anemia. 
According to the present and other studies, anemia of 
chronic disease (50%), anemia due to multiple causes 
(30%) and symptomatic treatment account for the 
highest percentage of anemias. Only a small percent-
age of cancer anemias are due to iron deficiency (in 
this study 11%) or hemolytic anemia (7.6%) and can 
be treated casually. Treatment of tumor anemia with 
hemoglobin values lower than 80 and clear symptoms 
of anemia requires RBC transfusion. Transfusion re-
mains a treatment option depending on the severity 
of anemia and clinical urgency of the situation. Some 
investigations have shown that patients who received 
blood transfusions under less rigorous conditions (Hb 
<= 100 g/L) had a higher mortality rate than patients 
who received transfusions under stringent criteria 
(Hb <= 70g/L). Milder anemia in practice is usually 
not treated13-15. At long term, tumor anemia can be 
corrected by ESA (epoetin alfa, epoetin beta, epoetin 
gamma and darbepoetin). ESA have shown good re-
sults in long term treatment of tumor anemia, with 
the response rate from 28% to 80%. The need of trans-
fusions, according to various studies, ranges from 9% 
to 50% of patients. ESA have been demonstrated ef-
fective in many patients with anemia in hematologic 
malignancies through achieving higher levels of he-
moglobin and reducing the need of transfusions. The 
result of successful treatment of lymphoid neoplasms 
is close to 80%. According to the American Soci-
ety of Clinical Oncology and the American Society 
of Hematology guidelines, it is recommended to use 
erythropoietin for the treatment of patients with che-
motherapy induced anemia whose hemoglobin con-
centration is less than 100 g/L2,3,5. In our study, it was 
26% of all patients. However, therapy with ESA has 
increased mortality due to the increased incidence of 
thromboembolic incidents, so it is not recommended 
to achieve hemoglobin values greater than 120 g/L. It 
also increases mortality due to stimulation of tumor 
growth, so the use of ESA products in patients with 
cancer is limited to the treatment of chemotherapy in-
duced anemia only16,17. 
In conclusion, the prevalence of anemia in lym-
phoid malignancies is high at the disease diagnosis, 
especially in MM patients, but comparison with other 
authors did not show any significant rise in the inci-
dence of anemia during chemotherapy. In MM and 
NHL patients, hemoglobin values improved by more 
than 100 g/L with the treatment, but worsening of the 
anemia was recorded in younger men. Accordingly, 
chemotherapy regimen in the treatment of lymphop-
roliferative disease mainly does not worsen anemia, 
and it is mostly a sign of the disease severity.
References   
1. BOKEMEYER C, LUDWIG H. Anemia in cancer, 2nd ed. 
London: Elsevier Health Sciences, 2005;292. 
2. TAS F, ERALP Y, BASARAN M, et al. Anemia in oncology 
practice: relation to diseases and their therapies. Am J Clin 
Oncol 2002;25:371-9.
3. HENRY D. Guidelines and recommendations for the man-
agement of anemia in patients with lymphoid malignancies. 
Drugs 2007;67:175-94.
4. STRAUS D, TESTA M, SAROKHAN B, et al. Quality of 
life and health benefits of early treatment of mild anemia: a 
randomized trial of epoetin alfa in patients receiving chemo-
therapy for hematologic malignancies. Cancer 2006;107:1909-
17.
5. RIZZO J, SOMERFILERD M, HAGERTY K, et al. Use 
of epoetin and darbepoetin in patients with cancer: 2007 
American Society of Hematology/American Society of 
Clinical Oncology clinical practice guideline update. Blood 
2008;111:25-41.
6. DURIE B, SALMON S. A clinical staging system for mul-
tiple myeloma. Cancer 1975;36:842-54.
7. HASENCLEAVER D, DIEHL V. A prognostic score for ad-
vanced Hodgkin’s disease. N Engl J Med 1998;339:1506-14.
8. CONLAN M, ARMITAGE J, et al. Clinical significance of 
hematologic parameters in non-Hodgkin’s lymphoma at di-
agnosis. Cancer 1991;67:1389-95.
500 Acta Clin Croat,  Vol. 50,   No. 4,  2011
Dubravka Županić-Krmek et al. Anemia in patients with lymphoid malignancies
  9. RAI K. Clinical staging of chronic lymphocytic leukemia. 
Blood 1975;46:219-30.
10. TOBENA M, SERRANO S, FERRER A, et al. Anemia 
oncologici evaluation in patients in the emergency room. J 
Clin Oncol 2009;27:Abst e20714.
11. BERNARDO G, AGLIETA M, AMADORA D, et al. 
Prevalence of anemia in oncologic patients treated with che-
motherapy. Italian survey at the national level. Recent Prog 
Med 2001;92:580-8.
12. GHOSH J, KUMAR L, SAxENA R, et al. A study of the 
prevalence and type of anemia in lymphoid malignancies. J 
Clin Oncol 2009(Suppl):Abstr e19556.
13. ENGERT A. Recombinant human erythropoietin as an al-
ternative to blood transfusion in cancer-related anemia. Dis 
Manage Health Outcomes 2000;8:259-72.
Sažetak
ANALIZA UTJECAJA RAZLIčITIH čIMBENIKA NA ANEMIJU U BOLESNIKA S LIMFATIčNIM 
NEOPLAZMAMA
D. Županić-Krmek, N. Lang, D. Jurčić, N. Ljubić i A. Bilić
Anemije su česta komplikacija kod limfatičnih neoplazma kao rezultat bolesti i mijelotoksične kemoterapije, a imaju 
značajan utjecaj na ishod liječenja, preživljenje i kvalitetu života. U istraživanje je bilo uključeno ukupno 55 bolesnika (32 
žene i 23 muškarca) s limfatičnim neoplazmama: 8 s kroničnom limfatičnom leukemijom (KLL), 17 s multiplim mijelo-
mom (MM) i 30 s ne-Hodgkinovim limfomom (NHL). Analiziran je utjecaj spola, dobi i tipa malignoma na učestalost, 
stupanj težine i tip anemije prije i nakon provedene kemoterapije. Učestalost anemija prije kemoterapije bila je 51,02%, a 
nakon provedene kemoterapije 55,31%. Najveća učestalost anemije prije kemoterapije utvrđena je kod MM (69%), potom 
kod NHL (44,4%) te KLL skupine (40,0%) na početku terapije. Nakon kemoterapije učestalost je bila kod MM 68,7%, 
NHL 20,8% te KLL 42,9%. Tijekom terapije rasla je i težina anemije u odnosu na stanje prije kemoterapije. Prevladavala 
je anemija kronične bolesti (53,8%), zatim anemija uslijed višestrukog mehanizma nastanka (30,7%), anemija zbog deficita 
željeza (11,5%) i hemolitična anemija (7,6%). Kod limfatičnih neoplazma visoka je učestalost anemija kao poseljedica bole-
sti, a pod utjecajem kemoterapije se nije značajnije povećala. Povećala se težina anemije. Budući da je prevladavala anemija 
1. stupnja prema SZO, samo manji broj bolesnika je zahtijevao transfuzijsko liječenje. Oko 26% svih bolesnika imalo je 
vrijednosti hemoglobina niže od 100 g/L tijekom kemoterapije i oni bi bili kandidati za liječenje sredstvom za stimuliranje 
eritropoeze radi poboljšanja kvalitete života. 
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